Breaking News, Collaborations & Alliances

Jubilant HollisterStier, Lilly Enter Bamlanivimab Mfg. Pact

COVID-19 therapy Bamlanivimab will be manufactured at Jubilant HollisterStier's Spokane, WA facility.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Jubilant Life Sciences Ltd., an integrated global pharmaceuticals and life sciences company, recently announced that its wholly-owned subsidiary, Jubilant Pharma Limited, through its contract manufacturing organization (CMO) subsidiary, Jubilant HollisterStier LLC, has signed a new contract with Eli Lilly for manufacturing of a treatment for COVID-19.   Lilly’s drug, Bamlanivimab, has been granted Emergency Use Authorization (EUA) by the FDA for emergency use as a treatment of COVID-19 and wil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters